CN112641100A - 一种含叶酸的抗抑郁冲剂 - Google Patents
一种含叶酸的抗抑郁冲剂 Download PDFInfo
- Publication number
- CN112641100A CN112641100A CN202011329571.1A CN202011329571A CN112641100A CN 112641100 A CN112641100 A CN 112641100A CN 202011329571 A CN202011329571 A CN 202011329571A CN 112641100 A CN112641100 A CN 112641100A
- Authority
- CN
- China
- Prior art keywords
- folic acid
- oil
- parts
- antidepressant
- stirring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 title claims abstract description 128
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 title claims abstract description 64
- 229960000304 folic acid Drugs 0.000 title claims abstract description 64
- 235000019152 folic acid Nutrition 0.000 title claims abstract description 64
- 239000011724 folic acid Substances 0.000 title claims abstract description 64
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims abstract description 52
- 239000008187 granular material Substances 0.000 claims abstract description 32
- DATAGRPVKZEWHA-UHFFFAOYSA-N L-gamma-glutamyl-n-ethylamine Natural products CCNC(=O)CCC(N)C(O)=O DATAGRPVKZEWHA-UHFFFAOYSA-N 0.000 claims abstract description 26
- 235000003805 Musa ABB Group Nutrition 0.000 claims abstract description 26
- 240000008790 Musa x paradisiaca Species 0.000 claims abstract description 26
- 235000015266 Plantago major Nutrition 0.000 claims abstract description 26
- 239000000843 powder Substances 0.000 claims abstract description 26
- 239000000935 antidepressant agent Substances 0.000 claims abstract description 25
- 230000001430 anti-depressive effect Effects 0.000 claims abstract description 24
- 229940005513 antidepressants Drugs 0.000 claims abstract description 24
- XCUCMLUTCAKSOZ-FIRIVFDPSA-N Liensinine Chemical compound C([C@@H]1C=2C=C(C(=CC=2CCN1C)OC)OC=1C(O)=CC=C(C=1)C[C@H]1N(C)CCC=2C=C(C(=CC=21)OC)OC)C1=CC=C(O)C=C1 XCUCMLUTCAKSOZ-FIRIVFDPSA-N 0.000 claims abstract description 22
- XCUCMLUTCAKSOZ-JSOSNVBQSA-N Liensinine Natural products C([C@@H]1C=2C=C(C(=CC=2CCN1C)OC)OC=1C(O)=CC=C(C=1)C[C@@H]1N(C)CCC=2C=C(C(=CC=21)OC)OC)C1=CC=C(O)C=C1 XCUCMLUTCAKSOZ-JSOSNVBQSA-N 0.000 claims abstract description 22
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 21
- 238000002360 preparation method Methods 0.000 claims abstract description 21
- 241000196324 Embryophyta Species 0.000 claims abstract description 3
- 239000003674 animal food additive Substances 0.000 claims abstract description 3
- 239000003921 oil Substances 0.000 claims description 63
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 36
- 238000003756 stirring Methods 0.000 claims description 27
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 18
- 241001300674 Plukenetia volubilis Species 0.000 claims description 17
- 238000002156 mixing Methods 0.000 claims description 14
- 239000002244 precipitate Substances 0.000 claims description 14
- 244000070406 Malus silvestris Species 0.000 claims description 13
- 235000005087 Malus prunifolia Nutrition 0.000 claims description 12
- 239000003995 emulsifying agent Substances 0.000 claims description 12
- 238000002791 soaking Methods 0.000 claims description 12
- 229920002101 Chitin Polymers 0.000 claims description 10
- 238000005303 weighing Methods 0.000 claims description 10
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 8
- 239000010779 crude oil Substances 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 239000001509 sodium citrate Substances 0.000 claims description 7
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 7
- 238000003825 pressing Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- -1 sucrose fatty acid ester Chemical class 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 238000000199 molecular distillation Methods 0.000 claims description 2
- 210000000582 semen Anatomy 0.000 claims description 2
- 229940080352 sodium stearoyl lactylate Drugs 0.000 claims description 2
- ODFAPIRLUPAQCQ-UHFFFAOYSA-M sodium stearoyl lactylate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O ODFAPIRLUPAQCQ-UHFFFAOYSA-M 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 16
- 239000003814 drug Substances 0.000 abstract description 6
- 239000000203 mixture Substances 0.000 abstract description 6
- 235000013305 food Nutrition 0.000 abstract description 5
- 230000007423 decrease Effects 0.000 abstract description 4
- 206010022998 Irritability Diseases 0.000 abstract description 3
- 230000002898 effect on depression Effects 0.000 abstract description 3
- 230000007774 longterm Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract description 2
- 230000006872 improvement Effects 0.000 abstract description 2
- 206010022437 insomnia Diseases 0.000 abstract description 2
- 230000036651 mood Effects 0.000 abstract description 2
- 235000019198 oils Nutrition 0.000 description 52
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- 230000000052 comparative effect Effects 0.000 description 19
- 239000000243 solution Substances 0.000 description 17
- 238000012360 testing method Methods 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 13
- 239000000725 suspension Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 9
- 238000001694 spray drying Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 230000009182 swimming Effects 0.000 description 7
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 230000003340 mental effect Effects 0.000 description 4
- 238000005192 partition Methods 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 241000202726 Bupleurum Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 101100370002 Mus musculus Tnfsf14 gene Proteins 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 2
- 229940012843 omega-3 fatty acid Drugs 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 239000005782 Fluopicolide Substances 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 1
- GIYXAJPCNFJEHY-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine hydrochloride (1:1) Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 201000009916 Postpartum depression Diseases 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 244000089698 Zanthoxylum simulans Species 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000002021 butanolic extract Substances 0.000 description 1
- 239000002034 butanolic fraction Substances 0.000 description 1
- 230000001612 cachectic effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- GBOYJIHYACSLGN-UHFFFAOYSA-N fluopicolide Chemical compound ClC1=CC(C(F)(F)F)=CN=C1CNC(=O)C1=C(Cl)C=CC=C1Cl GBOYJIHYACSLGN-UHFFFAOYSA-N 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960000389 fluoxetine hydrochloride Drugs 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- WABPQHHGFIMREM-UHFFFAOYSA-N lead(0) Chemical compound [Pb] WABPQHHGFIMREM-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960003955 mianserin Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000001627 myristica fragrans houtt. fruit oil Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- YZNWXXJZEDHRKB-UHFFFAOYSA-N octadecyl 2-hydroxypropanoate;sodium Chemical compound [Na].CCCCCCCCCCCCCCCCCCOC(=O)C(C)O YZNWXXJZEDHRKB-UHFFFAOYSA-N 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960004940 sulpiride Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B1/00—Production of fats or fatty oils from raw materials
- C11B1/06—Production of fats or fatty oils from raw materials by pressing
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B1/00—Production of fats or fatty oils from raw materials
- C11B1/10—Production of fats or fatty oils from raw materials by extracting
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于保健养生食品技术领域,具体涉及一种含叶酸的抗抑郁冲剂。所述含叶酸的抗抑郁冲剂,包括如下组分:印加果油、大蕉粉、L‑茶氨酸、叶酸、莲心碱。对于易怒、情绪波动大、精力明显减退,无原因的持续疲乏,失眠,早睡或睡眠过多,注意力集中困难或下降的抑郁者具有很好的改善作用,且制备方法简单,无毒副作用,适用于抑郁患者长期服用。
Description
技术领域
本发明属于保健养生食品技术领域,具体涉及一种含叶酸的抗抑郁冲剂。
背景技术
目前缓解精神压力和抗抑郁症的方法多采用西药治疗,如米安舍林、氟西汀、帕罗西汀、氟优草胺、舒必利等。另外,也有各种用于治疗抑郁症的汤药,如柴胡加龙骨牡蛎汤、柴胡解郁汤等。
如中国专利申请CN104353004A提供了柴胡加龙骨牡蛎汤治疗精神疾病的有效部位及其提取方法,按柴胡加龙骨牡蛎汤处方重量比例称取柴胡、龙骨、黄芩、生姜(切)、铅丹、人参、桂枝去皮、茯苓,半夏(洗)、大黄、牡蛎(熬)、大枣六枚,以上十二味加水煎煮,离心,上清浓缩后分别依次进行石油醚、乙酸乙酯、正丁醇萃取,将正丁醇部分进行真空干燥,粉碎得正丁醇提取物,粉碎、加蒸馏水溶解,过AB-8大孔吸附树脂柱,依次用水、10%乙醇水、30%乙醇水、50%乙醇水、70%乙醇水、90%乙醇水洗脱,收集10%洗脱液、浓缩、干燥得有效部位CLM-10%。对神经细胞的保护和修复作用明显提高,而且减少服用量,增强药物的顺应性。
缓解精神压力和抗抑郁功能食品主要有以下几大类功能成分:氨基酸、维生素、微量元素、脂肪酸和抗抑郁药草。氨基酸对振奋人的精神起着尤为重要的作用,缺乏会影响大脑神经递质等物质的合成,体内去甲肾上腺素的含量也会降低,使人萎靡不振、精神忧郁,维生素B族能对神经细胞起到抑制兴奋的作用,维生素B12参与脑中乙酰胆碱的合成维生素B6参与谷氨酸及其活体激活调节,而谷氨酸属于兴奋性神经递质之一,镁有抑制神经应激性的效用,摄入一定量的不饱和脂肪酸能降低抑郁症引发的心血管疾病,对心血管疾病卒中后抑郁有作用。据研究发现,不饱和脂肪酸与心血管病呈负相关,平均每天摄入400mgω-3脂肪酸可以降低抑郁症得病率,ω-3脂肪酸可对产后抑郁症有效。
以上这些治疗方法中有些效果并不明显,有些虽有效果但却具有副作用。因此能够利用食品中相关的有效成分开发缓解精神压力和抗抑郁的产品,具有巨大市场潜力。而目前市场上针对精神压力和抑郁症开发的保健食品十分罕见,部分抗抑郁产品成分单一或较少,只能在一定程度上缓解抑郁症,不能达到较理想的效果。
因此,有必要研究一种效果好且制备方法简单的缓解抑郁症的产品,使其有利于患者长期服用,无毒副作用。
发明内容
为克服以上技术问题,本发明提供了一种含叶酸的抗抑郁冲剂,该冲剂具有较好的效果,且制备方法简单,无毒副作用,适用于抑郁患者长期服用。
为实现以上目的,本发明提供的技术方案如下:
一种含叶酸的抗抑郁冲剂,包括以下组分:
印加果油、大蕉粉、L-茶氨酸、叶酸、莲心碱。
优选地,按照重量份数计,所述含叶酸的抗抑郁冲剂,包括以下组分:
印加果油25-33份、大蕉粉5-15份、L-茶氨酸1-8份、叶酸0.2-1份、莲心碱20-40份。
优选地,按照重量份数计,所述含叶酸的抗抑郁冲剂,包括以下组分:
印加果油29份、大蕉粉10份、L-茶氨酸4份、叶酸0.6份、莲心碱30份。
优选地,所述印加果油的制备方法包括以下步骤:
A:取印加果仁在柠檬酸钠溶液中浸泡,干燥后,冷榨,得到印加果粗油和压榨沉淀物;
B:向压榨沉淀物中加入柠檬酸溶液、甲壳素浸泡,搅拌,过滤,静置,收集表面油层,加入到印加果粗油中;
C:再将印加果粗油与乙酸溶液混合,搅拌,静置,收集表面油层,即得印加果油。
优选地,步骤A中,所述柠檬酸钠溶液的质量浓度为1-5%;
优选地,步骤A中,所述浸泡的时间为2-3h。
优选地,步骤B中,所述柠檬酸溶液的质量浓度为5-10%;
优选地,步骤B中,所述搅拌的转速为500-1000rpm。
优选地,步骤B中,所述甲壳素的加入质量为压榨沉淀物质量的3-8%;
优选地,步骤B中,所述柠檬酸溶液的加入质量为压榨沉淀物质量的30-60%。
优选地,步骤C中,所述乙酸溶液的质量浓度为3-5%;
优选地,步骤C中,所述搅拌的转速为100-500rpm。
优选地,步骤C中,所述柠檬酸溶液的加入质量为印加果粗油质量的1-2倍。
本发明的另一目的在于,提供所述含叶酸的抗抑郁冲剂的制备方法,包括以下步骤:
(1)称取印加果油、大蕉粉、莲心碱、L-茶氨酸、叶酸充分混匀;
(2)加入乳化剂,搅拌,干燥,即得。
优选地,步骤(1)中,所述乳化剂为分子蒸馏单甘酯或硬脂酰乳酸钠、蔗糖脂肪酸酯中的任一种。
优选地,步骤(1)中,所述搅拌的转速为10000-25000rpm,搅拌时间10-20min。
与现有技术比,本发明的技术优势在于:
(1)本发明提供的含有叶酸的抗抑郁冲剂,对于易怒、情绪波动大、精力明显减退,无原因的持续疲乏,失眠,早睡或睡眠过多,注意力集中困难或下降的抑郁者具有很好的改善作用,与单一缓解压力抗抑郁产品或者具有副作用的西药相比,具有明显的优势,是新型的保健品,具有良好的市场开发应用前景。
(2)本发明配伍合理,协同增效,不仅补充叶酸、缓解抑郁,而且原料中印加果油、大蕉粉、莲心碱、L-茶氨酸、叶酸搭配使用,全方合理配伍,药性平和,适合更多人群长期食用。
(3)本发明中印加果油采取冷榨的方式进行,制备过程中加入甲壳素有利于印加果油的提取制备。柠檬酸溶液的加入一方面可以溶解甲壳素,促进甲壳素在提取印加果油中发挥作用;另一方面在提取印加果油后有利于分离甲壳素。
具体实施方式
下面通过具体实施例对本发明进行说明,以使本发明技术方案更易于理解、掌握,但本发明并不局限于此。下述实施例中所述实验方法,如无特殊说明,均为常规方法;所述试剂和材料,如无特殊说明,均可从商业途径获得。
实施例1
一种印加果油的制备方法,包括以下步骤:
A:取印加果仁在质量浓度为5%的柠檬酸钠溶液中浸泡2h,干燥后,冷榨,得到印加果粗油和压榨沉淀物;
B:向压榨沉淀物中加入其30%质量的浓度为10%的柠檬酸溶液、3%质量的甲壳素浸泡,500rpm下搅拌,过滤,静置,收集表面油层,加入到印加果粗油中;
C:再将印加果粗油与1倍质量的浓度为3%的乙酸溶液混合,500rpm下搅拌,静置,收集表面油层,即得印加果油。
实施例2
一种印加果油的制备方法,包括以下步骤:
A:取印加果仁在质量浓度为1%的柠檬酸钠溶液中浸泡3h,干燥后,冷榨,得到印加果粗油和压榨沉淀物;
B:向压榨沉淀物中加入60%质量的浓度为5%的柠檬酸溶液、8%质量的甲壳素浸泡,1000rpm下搅拌,过滤,静置,收集表面油层,加入到印加果粗油中;
C:再将印加果粗油与2倍质量的浓度为5%的乙酸溶液混合,1000rpm下搅拌,静置,收集表面油层,即得印加果油。
实施例3
本例中,选用实施例1制备的印加果油。
所述含叶酸的抗抑郁冲剂,按照重量份数计,包括以下组分:
印加果油29份、大蕉粉10份、L-茶氨酸4份、叶酸0.6份、莲心碱30份。
所述含叶酸的抗抑郁冲剂的制备方法,包括以下步骤:
(1)称取印加果油、大蕉粉、莲心碱、L-茶氨酸、叶酸充分混匀;
(2)加入乳化剂分子蒸馏单甘酯,15000rpm下搅拌15min,喷雾干燥,即得。
实施例4
本例中,选用实施例2制备的印加果油。
所述含叶酸的抗抑郁冲剂,按照重量份数计,包括以下组分:
印加果油33份、大蕉粉5份、L-茶氨酸8份、叶酸0.2份、莲心碱40份。
所述含叶酸的抗抑郁冲剂的制备方法,包括以下步骤:
(1)称取印加果油、大蕉粉、莲心碱、L-茶氨酸、叶酸充分混匀;
(2)加入乳化剂蔗糖脂肪酸酯,25000rpm下搅拌10min,喷雾干燥,即得。
实施例5
本例中,选用市售(云小南)印加果油。
本例中,所述含叶酸的抗抑郁冲剂,按照重量份数计,包括以下组分:
印加果油25份、大蕉粉15份、L-茶氨酸1份、叶酸1份、莲心碱20份。所述含叶酸的抗抑郁冲剂的制备方法,包括以下步骤:
(1)称取印加果油、大蕉粉、莲心碱、L-茶氨酸、叶酸充分混匀;
(2)加入乳化剂硬脂酰乳酸钠,10000rpm下搅拌20min,喷雾干燥,即得。
对比例1
与实施例3相比,组分不同。
本例中,选用实施例1制备的印加果油。
所述含叶酸的抗抑郁冲剂,按照重量份数计,包括以下组分:
印加果油29份、大蕉粉10份、L-茶氨酸4份、叶酸0.6份、大豆多肽30份。
所述含叶酸的抗抑郁冲剂的制备方法,包括以下步骤:
(1)称取印加果油、大蕉粉、大豆多肽、L-茶氨酸、叶酸充分混匀;
(2)加入乳化剂分子蒸馏单甘酯,15000rpm下搅拌15min,喷雾干燥,即得。
对比例2
与实施例3相比,组分不同。
本例中,选用实施例1制备的印加果油。
所述含叶酸的抗抑郁冲剂,按照重量份数计,包括以下组分:
印加果油29份、大蕉粉10份、L-茶氨酸4份、叶酸0.6份、酸枣仁30份。
所述含叶酸的抗抑郁冲剂的制备方法,包括以下步骤:
(1)称取印加果油、大蕉粉、酸枣仁、L-茶氨酸、叶酸充分混匀;
(2)加入乳化剂分子蒸馏单甘酯,15000rpm下搅拌15min,喷雾干燥,即得。
对比例3
与实施例3相比,组分不同。
本例中,选用实施例1制备的印加果油。
所述含叶酸的抗抑郁冲剂,按照重量份数计,包括以下组分:
印加果油29份、大蕉粉10份、L-茶氨酸4份、叶酸3份、莲心碱30份。
所述含叶酸的抗抑郁冲剂的制备方法,包括以下步骤:
(1)称取印加果油、大蕉粉、莲心碱、L-茶氨酸、叶酸充分混匀;
(2)加入乳化剂分子蒸馏单甘酯,15000rpm下搅拌15min,喷雾干燥,即得。
对比例4
与实施例3相比,组分不同。
本例中,选用实施例1制备的印加果油。
所述含叶酸的抗抑郁冲剂,按照重量份数计,包括以下组分:
印加果油29份、大蕉粉10份、L-茶氨酸4份、叶酸0.05份、莲心碱30份。
所述含叶酸的抗抑郁冲剂的制备方法,包括以下步骤:
(1)称取印加果油、大蕉粉、莲心碱、L-茶氨酸、叶酸充分混匀;
(2)加入乳化剂分子蒸馏单甘酯,15000rpm下搅拌15min,喷雾干燥,即得。
对比例5
与实施例3相比,印加果油的制备方法不同。
一种印加果油的制备方法,包括以下步骤:
A:取印加果仁在质量浓度为5%的柠檬酸钠溶液中浸泡2h,干燥后,冷榨,得到印加果粗油和压榨沉淀物;
B:向压榨沉淀物中加入其30%质量的浓度为10%的柠檬酸溶液浸泡,500rpm下搅拌,过滤,静置,收集表面油层,加入到印加果粗油中,制得印加果油。
将制得的印加果油用于制备含叶酸的抗抑郁冲剂,按照重量份数计,包括以下组分:
印加果油29份、大蕉粉10份、L-茶氨酸4份、叶酸0.6份、莲心碱30份。
所述含叶酸的抗抑郁冲剂的制备方法,包括以下步骤:
(1)称取印加果油、大蕉粉、莲心碱、L-茶氨酸、叶酸充分混匀;
(2)加入乳化剂分子蒸馏单甘酯,15000rpm下搅拌15min,喷雾干燥,即得。
效果试验
1.小鼠试验
采用验证焦虑抑郁症的常规动物实验:悬尾试验和强迫游泳试验、明暗箱试验进行。
昆明种雄性小鼠,体重18-22g。实验环境温度20-24℃,湿度50%-60%。小鼠自由摄食和饮水,实验前适应5天,复查合格后开始正式实验。
小鼠随机分为10组,分别为模型组、阳性组、本发明实施例3-5和对比例1-5组;每组10只。实施例3-5和对比例1-5组的喂食量为0.5g/kg,阳性组为盐酸氟西汀(剂量0.01g/kg),实施例组、对比例组以及药物组用生理盐水配成混悬液;模型组在给药期间注射等剂量生理盐水。每日1次,每天灌胃给药一次,连续灌胃给药14天,末次给药2h后测试。
(1)小鼠悬尾试验
小鼠悬尾试验主要是通过固定小鼠尾部使其头向下悬挂,小鼠在该环境中处于恐慌而拼命挣扎逃跑,又无法逃脱的状态,给小鼠提供一个无法回避的压迫环境,一段时间后,记录处于该环境下的小鼠产生绝望的不动状态过程的不动时间,以观察给药后的治疗效果。将小鼠尾端粘在悬尾箱上部的支架上,将其成为倒吊状态进行悬尾实验。倒挂小鼠的头部距离箱底10cm,一次悬挂2只小鼠,中间用隔板隔开以免碰撞。小鼠在倒挂后由于恐慌会进行挣扎活动,当挣扎疲劳后会处于失望状态而出现间断性不动。悬挂小鼠10分钟,统计后5分钟内悬尾倒挂小鼠累计不动时间。结果见表1:
表1小鼠悬尾试验
试验组 | 悬尾不动时间(s) |
模型组 | 126.17±6.29 |
阳性组 | 64.09±4.31** |
实施例3 | 77.95±9.28** |
实施例4 | 78.14±7.11** |
实施例5 | 81.23±6.14** |
对比例1 | 91.74±11.19* |
对比例2 | 89.31±13.27* |
对比例3 | 83.17±10.60** |
对比例4 | 87.37±5.18* |
对比例5 | 94.35±8.23* |
注:与模型组相比,*p<0.05;**p<0.01。
(2)强迫游泳试验
通过将实验小鼠置于一个局限的水中,小鼠在该环境中拼命挣扎试图逃跑又无法逃脱,提供了一个无可回避的压迫环境,一段时间的实验后,小鼠即表现出典型的行为绝望状态的不动状态,记录小鼠产生绝望的不动状态时的不动时间,以观察用药后的治疗效果。将小鼠放入长50cm,宽40cm,高40cm的塑料游泳箱中做强迫性游泳试验,从小鼠放入水中后计时10分钟,记录后5分钟内小鼠仅有微小肢体运动而不挣扎、显示休息和漂浮状态的累计不动时间。结果见表2:
表2小鼠强迫游泳试验
试验组 | 游泳不动时间(s) |
模型组 | 128.47±9.64 |
阳性组 | 80.11±6.23** |
实施例3 | 90.25±8.69** |
实施例4 | 91.93±9.37** |
实施例5 | 93.17±11.29** |
对比例1 | 106.24±14.57* |
对比例2 | 98.53±7.39** |
对比例3 | 96.16±10.06** |
对比例4 | 101.45±9.25* |
对比例5 | 95.29±7.63** |
注:与模型组相比,*p<0.05;**p<0.01。
从表1-2看出,与模型组对比,阳性组和实施例1-5组小鼠的悬尾试验不动时间和游泳试验不动时间均显著降低,且具有显著性差异,表明本发明的实施例1-5具有明显的缓解焦虑抑郁症状的作用;由对比例1-4的实验数据可知,本发明中缓解抑郁产品中组成组分对缓解抑郁的效果具有较大的影响。
(3)小鼠明暗箱试验
将木箱制成一个上面敞开的箱子,内部分为明箱和暗箱,明箱占箱子的3/5,暗箱占2/5,中间用一隔板分开,隔板的底部开一方口。明箱内涂成白色,由一个白炽灯泡照明,暗箱内涂成黑色,上方置一个不通电的红色灯泡。箱子底部划上边长9cm的方格。动物置于暗箱红灯不通电,明箱白炽灯照明,造成动物焦虑。将小鼠放入明箱中央,背朝隔板,观察小鼠在10分钟内在明暗箱中穿梭次数,穿梭次数越多,说明小鼠的焦虑越严重。结果见表3:
表3小鼠明暗箱穿梭试验
注:与模型组相比,*p<0.05;**p<0.01。
由此可知,本发明的产品对缓解抑郁症状具有明显的效果,且产品的组成组分对其效果具有重要的影响。
上述详细说明是针对本发明其中之一可行实施例的具体说明,该实施例并非用以限制本发明的专利范围,凡未脱离本发明所为的等效实施或变更,均应包含于本发明技术方案的范围内。
Claims (10)
1.一种含叶酸的抗抑郁冲剂,包括以下组分:
印加果油、大蕉粉、L-茶氨酸、叶酸、莲心碱。
2.如权利要求1所述的含叶酸的抗抑郁冲剂,其特征在于,按照重量份数计,所述含叶酸的抗抑郁冲剂,包括以下组分:印加果油25-33份、大蕉粉5-15份、L-茶氨酸1-8份、叶酸0.2-1份、莲心碱20-40份。
3.如权利要求1所述的含叶酸的抗抑郁冲剂,其特征在于,按照重量份数计,所述含叶酸的抗抑郁冲剂,包括以下组分:印加果油29份、大蕉粉10份、L-茶氨酸4份、叶酸0.6份、莲心碱30份。
4.如权利要求1-3任一所述的含叶酸的抗抑郁冲剂,其特征在于,所述印加果油的制备方法包括以下步骤:
A:取印加果仁在柠檬酸钠溶液中浸泡,干燥后,冷榨,得到印加果粗油和压榨沉淀物;
B:向压榨沉淀物中加入柠檬酸溶液、甲壳素浸泡,搅拌,过滤,静置,收集表面油层,加入到印加果粗油中;
C:再将印加果粗油与乙酸溶液混合,搅拌,静置,收集表面油层,即得印加果油。
5.如权利要求4所述的含叶酸的抗抑郁冲剂,其特征在于,步骤A中,所述柠檬酸钠溶液的质量浓度为1-5%;所述浸泡的时间为2-3h。
6.如权利要求4所述的含叶酸的抗抑郁冲剂,其特征在于,步骤B中,所述柠檬酸溶液的质量浓度为5-10%;所述搅拌的转速为500-1000rpm;所述甲壳素的加入质量为压榨沉淀物质量的3-8%;所述柠檬酸溶液的加入质量为压榨沉淀物质量的30-60%。
7.如权利要求4所述的含叶酸的抗抑郁冲剂,其特征在于,步骤C中,所述乙酸溶液的质量浓度为3-5%;所述搅拌的转速为100-500rpm;所述柠檬酸溶液的加入质量为印加果粗油质量的1-2倍。
8.如权利要求1-7任一所述含叶酸的抗抑郁冲剂的制备方法,其特征在于,包括以下步骤:
(1)称取印加果油、大蕉粉、莲心碱、L-茶氨酸、叶酸充分混匀;
(2)加入乳化剂,搅拌,干燥,即得。
9.如权利要求8所述含叶酸的抗抑郁冲剂的制备方法,其特征在于,步骤(1)中,所述乳化剂为分子蒸馏单甘酯或硬脂酰乳酸钠、蔗糖脂肪酸酯中的任一种。
10.如权利要求8所述含叶酸的抗抑郁冲剂的制备方法,其特征在于,步骤(1)中,所述搅拌的转速为10000-25000rpm,搅拌时间10-20min。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011329571.1A CN112641100A (zh) | 2020-11-24 | 2020-11-24 | 一种含叶酸的抗抑郁冲剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011329571.1A CN112641100A (zh) | 2020-11-24 | 2020-11-24 | 一种含叶酸的抗抑郁冲剂 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112641100A true CN112641100A (zh) | 2021-04-13 |
Family
ID=75349349
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011329571.1A Pending CN112641100A (zh) | 2020-11-24 | 2020-11-24 | 一种含叶酸的抗抑郁冲剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112641100A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114224919A (zh) * | 2021-11-30 | 2022-03-25 | 北京斯利安健康科技有限公司 | 一种缓解抑郁的药物组合物及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006005219A1 (fr) * | 2004-05-27 | 2006-01-19 | Chengdu Kanghong Technology Enterprises (Group) Co., Ltd. | Composition pharmaceutique pour traiter la depression, et procede pour la preparer |
WO2009000145A1 (fr) * | 2007-06-25 | 2008-12-31 | Zuoguang Zhang | Utilisation et preparation de paeoniflorine et composition associee |
CN102228255A (zh) * | 2011-05-18 | 2011-11-02 | 广州智享生物科技有限公司 | 可缓解精神压力和抗抑郁的营养冲剂及制备方法 |
CN108354972A (zh) * | 2018-04-20 | 2018-08-03 | 中南大学湘雅医院 | 莲子心提取物在制药中的应用 |
CN108587773A (zh) * | 2018-04-26 | 2018-09-28 | 国家林业局桉树研究开发中心 | 一种印加果油的生产工艺 |
-
2020
- 2020-11-24 CN CN202011329571.1A patent/CN112641100A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006005219A1 (fr) * | 2004-05-27 | 2006-01-19 | Chengdu Kanghong Technology Enterprises (Group) Co., Ltd. | Composition pharmaceutique pour traiter la depression, et procede pour la preparer |
WO2009000145A1 (fr) * | 2007-06-25 | 2008-12-31 | Zuoguang Zhang | Utilisation et preparation de paeoniflorine et composition associee |
CN102228255A (zh) * | 2011-05-18 | 2011-11-02 | 广州智享生物科技有限公司 | 可缓解精神压力和抗抑郁的营养冲剂及制备方法 |
CN108354972A (zh) * | 2018-04-20 | 2018-08-03 | 中南大学湘雅医院 | 莲子心提取物在制药中的应用 |
CN108587773A (zh) * | 2018-04-26 | 2018-09-28 | 国家林业局桉树研究开发中心 | 一种印加果油的生产工艺 |
Non-Patent Citations (1)
Title |
---|
高娜娜 等: ""莲心碱对抑郁症模型小鼠的抗抑郁作用"", 《神经疾病与精神卫生》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114224919A (zh) * | 2021-11-30 | 2022-03-25 | 北京斯利安健康科技有限公司 | 一种缓解抑郁的药物组合物及其制备方法 |
CN114224919B (zh) * | 2021-11-30 | 2024-06-25 | 北京斯利安健康科技有限公司 | 一种缓解抑郁的药物组合物及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1625406A (zh) | 用于预防和治疗温血动物的应激状态的含有溶血磷脂酰丝氨酸的制剂 | |
CN103859379A (zh) | 一种有助于改善记忆的养生保健食品配方及其制备方法 | |
CN112315995A (zh) | 一种含有元宝枫籽油的组合物及其制备方法 | |
CN107853517B (zh) | 一种提神抗疲劳的中药饮料及其制备方法 | |
CN111329907A (zh) | 一种具有抗缺氧功能的芫根组合物及其制备方法和应用 | |
CN111840394B (zh) | 一种用于失眠的药物组合物及其制备方法 | |
CN101711840B (zh) | 一种适用于癌症患者的药食两用组合物及其制备方法 | |
CN112641100A (zh) | 一种含叶酸的抗抑郁冲剂 | |
CN104171485A (zh) | 一种抗衰老蜂蜜 | |
CN109430854B (zh) | 一种保健品及其制备方法 | |
CN110772564A (zh) | 一种具有调节抑郁情绪作用的中药提取物组合物及其制备方法和中药制剂 | |
CN106360076A (zh) | 肉鸡雏鸡饲料 | |
KR101910013B1 (ko) | 한약재 추출물(socg)을 함유하는 통증의 개선, 예방 또는 치료용 조성물 | |
CN101745042B (zh) | 一种具有解酒保肝作用的组合物及其制备方法 | |
CN104256618B (zh) | 一种降血糖的食品、保健品或药物组合物 | |
CN104013696B (zh) | 一种防治代谢综合征的植物药组合物及其应用 | |
JP2004352626A (ja) | 植物由来成分を含有する抗コレステロール剤 | |
CN103417808A (zh) | 一种镇静安神的中兽药 | |
CN108813500B (zh) | 具有补中益气、养血安神和调节人体机能的养生蜂蜜膏 | |
CN109805235B (zh) | 一种辅助降四高的麦香复合多肽固体饮料、制备方法及用途 | |
CN102631503A (zh) | 一种抗疲劳中药组合物及其制备方法 | |
CN107536016B (zh) | 一种保护心脏和促进肝脏健康的营养食品 | |
CN106727915B (zh) | 一种稳定高效提高记忆的组合物及其制备方法和应用 | |
CN105285977A (zh) | 一种具有抗衰老、提高免疫力功效的保健品 | |
CN1686514A (zh) | 治疗焦虑症、抑郁症的中药制剂及其生产方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |